Eunomia perspective · 2026-02-16 · HCP Engagement & Transparency Reporting

Transparency Reporting in the Pharmaceutical Industry: Legal Compliance Versus Ethical Responsibility

Published by Eunomia Pharma Services · Updated 30 September 2026

What does pharmaceutical transparency reporting involve?

Transparency reporting involves identifying, reconciling and disclosing reportable transfers of value under the rules applicable to a company, recipient and market. Those rules can arise from legislation or industry-code commitments, and they are not identical across countries. An operational process connects engagement records and finance data to the relevant disclosure categories, with documented checks before publication.

Build disclosure into the engagement workflow

Confirm scope for each market: applicable law or code, covered entities and recipients, reporting categories and current deadlines.
Collect usable records at source: recipient details, engagement purpose, payment or benefit, dates and supporting identifiers.
Reconcile the records: compare engagement systems, finance and agency data; investigate missing entries and duplicate payments.
Approve and retain: document corrections, the reporting methodology and final sign-off, then preserve the evidence behind the disclosure.

The practical steps above are Eunomia’s operational guidance. See the source notes below for the scope of the external references.

Transparency reporting in the pharmaceutical industry has evolved from a niche compliance requirement into a central pillar of corporate governance and public accountability. What was once viewed as an administrative obligation is now recognised as a visible indicator of how organisations conduct themselves within healthcare systems.

For many pharmaceutical companies, transparency reporting is still associated with annual disclosure cycles, internal reconciliations, regulatory deadlines, and audit readiness. It is often treated as a technical exercise owned by compliance or legal teams, largely disconnected from day-to-day business decisions. This narrow framing underestimate both the purpose and the impact of transparency reporting.

Pharmaceutical companies influence clinical practice, research priorities, and patient access to medicines. Financial interactions with healthcare professionals (HCPs), healthcare organisations (HCOs), and patient groups are legitimate and often necessary. Without transparency, however, these relationships risk being misunderstood, misrepresented, or mistrusted. Transparency reporting exists to bridge this gap between collaboration and accountability.

This leads to a fundamental question: is transparency reporting merely a legal requirement, or does it reflect a broader ethical responsibility? While transparency frameworks are rooted in law and self-regulation, their true value lies in how ethically they are implemented.

The legal foundations: Sunshine laws and self-regulation

Globally, transparency reporting emerged in response to concerns around conflicts of interest in healthcare. In the United States, the Physician Payments Sunshine Act mandates public disclosure of certain transfers of value to physicians and teaching hospitals. In Europe, while there is no single pan-European statute, transparency obligations arise through a combination of industry self-regulation and national legislation. Countries such as France and Portugal have established statutory disclosure requirements that go beyond voluntary industry codes, making transparency reporting a legal obligation rather than a matter of membership. Other jurisdictions, including Italy, are moving in the same direction, with new national transparency legislation adopted and expected to come into force through implementing measures. This trend reflects a broader shift across Europe, where an increasing number of countries are either introducing or strengthening legally binding transparency frameworks alongside existing self-regulatory models.

In both models, transparency reporting is either legally required by statute or contractually mandatory for members of industry self-regulatory bodies. Compliance is not optional. Organisations must disclose defined categories of transfers of value, follow prescribed timelines, and publish data in approved formats. Regulators and industry bodies assess compliance against objective criteria: completeness, accuracy, and timeliness.

These frameworks establish a critical baseline. They create consistency, comparability, and a minimum standard of accountability across the industry. However, they are designed to address known risks, not evolving expectations.

The limits of compliance alone

Legal compliance answers the question of what must be disclosed. It does not always answer how disclosures will be interpreted. A purely compliance-driven approach often leads to rigid rule-following, where decisions are justified because they are technically permissible, even if they undermine clarity or trust.

In practice, this can result in disclosures that are formally compliant but difficult to understand, poorly contextualised, or fragmented across systems and markets. Transparency becomes retrospective and transactional: data is gathered after the fact, reconciled under pressure, and published with limited strategic oversight. This increases the risk of errors, inconsistencies, and reputational exposure.

Transparency as an ethical responsibility

Ethical transparency goes beyond minimum legal requirements. It recognises that pharmaceutical companies have a responsibility to maintain public trust, even where the law is silent, fragmented, or open to interpretation. While transparency reporting frameworks focus on disclosure, ethical transparency is closely linked to broader integrity obligations, including anti-bribery and anti-corruption (ABAC) laws, anti-kickback principles, and fair market value (FMV) standards.

Financial interactions that are fully disclosed may still raise ethical concerns if they are poorly justified, misaligned with FMV, or perceived as influencing clinical or purchasing decisions. Ethical transparency therefore asks not only whether a transfer of value is reported, but why it exists, how it was determined, and whether it can be credibly defended. It evaluates disclosures against organisational values and intent, not just technical compliance thresholds.

Patients, journalists, regulators, and the public do not interpret transparency data through regulatory definitions or legal exemptions. They interpret it through the lens of credibility, proportionality, and purpose. A payment that is lawful and disclosed can still undermine trust if it appears excessive, inconsistent, or insufficiently explained. Ethical transparency acknowledges this gap between legal permissibility and public perception.

Embedding ethics into transparency in practice

Putting ethical transparency into practice requires governance, not just reporting. It means integrating transparency considerations upstream into contracting, engagement planning, FMV assessments, and payment processes, rather than treating disclosure as a downstream correction exercise.

Ethical organisations maintain clear documentation of decision-making, apply FMV principles consistently, and ensure alignment between transparency reporting, ABAC controls, and engagement rationale. This requires cross-functional ownership across compliance, legal, medical, finance, and commercial teams, supported by clear policies and decision frameworks.

Organisations that embed transparency into their operating model reduce reliance on defensive explanations, strengthen audit defensibility, and demonstrate that disclosures reflect considered judgement rather than box-ticking.

Beyond compliance

Transparency reporting begins with the law, but it achieves its purpose through ethics. Legal compliance protects organisations from regulatory sanctions and enforcement risk. Ethical transparency protects organisations from reputational harm, erosion of trust, and long-term credibility risk.

At Eunomia Pharma Services, we believe that compliance keeps organisations compliant but ethics makes them credible. In an industry built on trust, credibility is not optional.

Sources and scope

EFPIA: Code of Practice and supporting guidance
European industry-code framework. Check the relevant national implementation and any additional statutory requirements.
CMS: Open Payments
The US programme provides a separate statutory reporting example. Its scope and processes should not be substituted for European requirements.

External sources accessed 30 September 2026. Check the applicable country rules and current source text for a specific engagement.